Zobrazeno 1 - 10
of 530
pro vyhledávání: '"Raymond K. Cross"'
Autor:
PR Newswire
Publikováno v:
PR Newswire US. 07/18/2024.
Autor:
Madeline Alizadeh, Uni Wong, Bernadette C. Siaton, Seema A. Patil, Lauren George, Jean-Pierre Raufman, William H. Scott, Erik C. von Rosenvinge, Jacques Ravel, Raymond K. Cross
Publikováno v:
Heliyon, Vol 10, Iss 4, Pp e26571- (2024)
Background: Inflammatory Bowel Disease (IBD)-associated arthritis is a frequent and potentially debilitating complication of IBD, that can affect those with or without active intestinal disease, and is often difficult to treat. The microbiome is know
Externí odkaz:
https://doaj.org/article/326a44670ac74751b5faba920544b242
Autor:
Douglas C. Wolf, April N. Naegeli, Page C. Moore, Jud C. Janak, Margaux M. Crabtree, Mingyang Shan, Theresa M. Hunter, Angelina Sontag, Raymond K. Cross
Publikováno v:
Gastro Hep Advances, Vol 2, Iss 6, Pp 799-809 (2023)
Background and Aims: Fecal urgency is a common symptom of Ulcerative Colitis (UC). We explored the association between changes in fecal urgency for patient characteristics and evaluated the association between change in treatment and change in fecal
Externí odkaz:
https://doaj.org/article/d0559694a29d41378ca38f9362f5054c
Autor:
Lauren A. George, Erin Causey, Nisha B. Shah, James C. Slaughter, Jonah Jerabek, Autumn D. Zuckerman, Susan Chhen, Elizabeth Scoville, Robin Dalal, Dawn B. Beaulieu, Baldeep Pabla, David A. Schwartz, Raymond K. Cross, Byron P. Vaughn, Sara Horst
Publikováno v:
Gastro Hep Advances, Vol 2, Iss 4, Pp 601-607 (2023)
Background and Aims: This study aimed to evaluate adherence to subcutaneous biologic therapy and impact of nonadherence including risk factors and outcomes in academic centers with integrated specialty pharmacies for patients with inflammatory bowel
Externí odkaz:
https://doaj.org/article/4f3c4c2679b740fb9053d33568e5f99c
Autor:
Raymond K. Cross, Jenny S. Sauk, Joe Zhuo, Ryan W. Harrison, Samantha J. Kerti, Kelechi Emeanuru, Jacqueline O’Brien, Harris A. Ahmad, Antoine G. Sreih, Joehl Nguyen, Sara N. Horst, David Hudesman
Publikováno v:
Gastro Hep Advances, Vol 1, Iss 6, Pp 927-935 (2022)
Background and Aims: This study aimed to evaluate associations between disease severity, patient-reported outcomes (PROs), and work productivity in patients with inflammatory bowel disease (IBD [Crohn’s disease (CD) and ulcerative colitis (UC)]). M
Externí odkaz:
https://doaj.org/article/a966b9317578497aac871332a9cb970d
Autor:
Sumona Bhattacharya, Raymond K. Cross
Publikováno v:
European Medical Journal Gastroenterology, Vol 9, Iss 1, Pp 91-101 (2020)
Inflammatory bowel disease, consisting of Crohn’s disease and ulcerative colitis, causes chronic gastrointestinal symptoms and can lead to morbidity and mortality if uncontrolled or untreated. However, for patients with moderate-to-severe disease,
Externí odkaz:
https://doaj.org/article/f76fe834e0164a2eaaf2c60565296fea
Publikováno v:
Digestive Diseases and Sciences. 68:380-384
Publikováno v:
Case Reports in Medicine, Vol 2020 (2020)
When evaluating a patient with acute onset unilateral leg pain and concurrent inflammatory bowel disease (IBD), keeping a broad differential diagnosis will allow for prompt diagnosis and management. The patient described in this case report is a 32-y
Externí odkaz:
https://doaj.org/article/eef601db2d1a4d229a387eb0b9a0d380
Autor:
Sophie Shubow, Qin Sun, Ai Len Nguyen Phan, Dana C. Hammell, Maureen Kane, Gary H. Lyman, Allan Gibofsky, Gary R. Lichtenstein, Zachary Bloomgarden, Raymond K. Cross, Sarah Yim, James E. Polli, Yow‐Ming Wang
Publikováno v:
Clinical Pharmacology & Therapeutics. 113:37-49
The approval and adoption of biosimilar products are essential to contain increasing healthcare costs and provide more affordable choices for patients. Despite steady progress in the number of the US Food and Drug Administration (FDA) biosimilar appr
Publikováno v:
Gastrointestinal Endoscopy Clinics of North America. 32:675-686